These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22380682)

  • 1. Dolutegravir for the treatment of HIV.
    Katlama C; Murphy R
    Expert Opin Investig Drugs; 2012 Apr; 21(4):523-30. PubMed ID: 22380682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.
    Saladini F; Meini G; Bianco C; Monno L; Punzi G; Pecorari M; Borghi V; Di Pietro M; Filice G; Gismondo MR; Micheli V; Penco G; Carli T; De Luca A; Zazzi M;
    Clin Microbiol Infect; 2012 Oct; 18(10):E428-30. PubMed ID: 22716970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dolutegravir: an exciting new kid on the block.
    Blanco Arévalo JL; Whitlock GG
    Expert Opin Pharmacother; 2014 Mar; 15(4):573-82. PubMed ID: 24446762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
    Shah BM; Schafer JJ; Desimone JA
    Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.
    Rathbun RC; Lockhart SM; Miller MM; Liedtke MD
    Ann Pharmacother; 2014 Mar; 48(3):395-403. PubMed ID: 24259658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
    Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
    J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
    Akil B; Blick G; Hagins DP; Ramgopal MN; Richmond GJ; Samuel RM; Givens N; Vavro C; Song IH; Wynne B; Ait-Khaled M;
    Antivir Ther; 2015; 20(3):343-8. PubMed ID: 25321146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging patterns and implications of HIV-1 integrase inhibitor resistance.
    Geretti AM; Armenia D; Ceccherini-Silberstein F
    Curr Opin Infect Dis; 2012 Dec; 25(6):677-86. PubMed ID: 23086187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of dolutegravir in treatment-experienced patients: the SAILING and VIKING trials].
    Moreno S; Berenguer J
    Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():26-30. PubMed ID: 25858609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrase strand transfer inhibitors in the management of HIV-positive individuals.
    Mesplède T; Quashie PK; Zanichelli V; Wainberg MA
    Ann Med; 2014 May; 46(3):123-9. PubMed ID: 24579911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel integrase inhibitors for HIV.
    Prada N; Markowitz M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges.
    Lenz JC; Rockstroh JK
    Expert Opin Investig Drugs; 2011 Apr; 20(4):537-48. PubMed ID: 21381981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug safety profile of integrase strand transfer inhibitors.
    Gutierrez Mdel M; Mateo MG; Vidal F; Domingo P
    Expert Opin Drug Saf; 2014 Apr; 13(4):431-45. PubMed ID: 24597519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection.
    Osterholzer DA; Goldman M
    Clin Infect Dis; 2014 Jul; 59(2):265-71. PubMed ID: 24723281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France.
    Pialoux G; Marcelin AG; Despiégel N; Espinas C; Cawston H; Finkielsztejn L; Laurisse A; Aubin C
    PLoS One; 2015; 10(12):e0145885. PubMed ID: 26714188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Might dolutegravir be part of a functional cure for HIV?
    Wainberg MA; Han YS; Mesplède T
    Can J Microbiol; 2016 May; 62(5):375-82. PubMed ID: 27031127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV type 1 integrase inhibitors: from basic research to clinical implications.
    Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
    AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New first and second generation inhibitors of human immunodeficiency virus-1 integrase.
    Pendri A; Meanwell NA; Peese KM; Walker MA
    Expert Opin Ther Pat; 2011 Aug; 21(8):1173-89. PubMed ID: 21599420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.
    Ceccherini-Silberstein F; Malet I; Fabeni L; Dimonte S; Svicher V; D'Arrigo R; Artese A; Costa G; Bono S; Alcaro S; Monforte Ad; Katlama C; Calvez V; Antinori A; Marcelin AG; Perno CF
    J Antimicrob Chemother; 2010 Nov; 65(11):2305-18. PubMed ID: 20817922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Integrase inhibitor in HIV therapy. Does dolutegravir set new standards?].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():58-9. PubMed ID: 25026862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.